A Tissue and Longitudinal Circulating Tumor DNA (ctDNA) Biomarker Profiling Study of Patients with Small Cell Lung Cancer (SCLC) Using Comprehensive Next-Generation Sequencing (NGS) Assays (TEMPUS)
Study Number: TP-CA-003
Study Summary:
The study is a non-interventional evaluation of participants with SCLC who will receive diagnostic and (where possible) post-progression tumor tissue profiling, alongside plasma ctDNA biomarker profiling in addition to their standard of care therapy and disease surveillance.
Status: Open
Bloomington, Canton, Galesburg, Ottawa, Pekin, Peoria, Peru, Washington clinics
Study Coordinator(s)
- Trupti, 309-243-3662, thattiangadi@illinoiscancercare.com
